News & Updates

A recent study has provided a detailed proteomic profile that identified proteins associated with the pathogenesis and disease progression of chronic obstructive pulmonary disease (COPD), which can then help in the creation of platform to develop effective new treatment strategies.

A recent multi-ethnic Singapore study confirms that asthma is a common disease, affecting more than 10 percent of adults, especially former smokers and those with high body mass index (BMI). Asthma is also associated with worse health-related quality of life (HRQoL), making it a substantial public health concern.

In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.

The Spike single-nucleotide polymorphism (SNP) assay, a single-reaction multiplex real-time RT-PCR, provides fast, inexpensive, and sensitive detection of specific mutations associated with SARS-CoV-2 variants of concern (VoC), according to data presented at ID Week 2021.

Patients on sodium-glucose co-transporter (SGLT) 2 inhibitors are less likely to develop asthma compared with those on dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), a study has found.

Households, and not schools, are the major route of coronavirus disease 2019 (COVID-19) transmission for those ≤18 years of age, according to a cross-sectional study of nearly 400 Hong Kong children and youths who contracted COVID-19 in 2020.

A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).

Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.

An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.